Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Journal of Hematology
Published in: International Journal of Hematology 3/2014

01-03-2014 | Images in Hematology

Acute myeloid leukemia of mixed megakaryocytic and erythroid origin following chemotherapy for T-cell lymphoblastic lymphoma

Authors: Woori Jang, Myungshin Kim, Jae Wook Lee, Nack-Gyun Chung

Published in: International Journal of Hematology | Issue 3/2014

Login to get access

Excerpt

A 14-year-old boy was admitted for fever of 3-day duration, and palpable masses in his left axilla and breast for 1 month. Four years prior to admission, he had been diagnosed with mediastinal T-lymphoblastic lymphoma without evidence of bone marrow (BM) involvement, and had received induction chemotherapy with dexamethasone, vincristine, daunorubicin, and l-asparaginase, resulting in complete remission. The patient had completed subsequent phases of consolidation and maintenance treatment and had been off treatment for 18 months before admission. …
Literature
1.
Daniëls L, Guerti K, Vermeulen K, et al. Acute myeloid leukaemia of mixed megakaryocytic and erythroid origin: a case report and review of the literature. Acta Clin Belg. 2007;62(5):308–14.PubMedCrossRef
2.
Linari S, Vannucchi AM, Ciolli S, et al. Coexpression of erythroid and megakaryocytic genes in acute erythroblastic (FAB M6) and megakaryoblastic (FAB M7) leukaemias. Br J Haematol. 1998;102(5):1335–7.PubMedCrossRef
Metadata
Title
Acute myeloid leukemia of mixed megakaryocytic and erythroid origin following chemotherapy for T-cell lymphoblastic lymphoma
Authors
Woori Jang
Myungshin Kim
Jae Wook Lee
Nack-Gyun Chung
Publication date
01-03-2014
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 3/2014
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-014-1512-3

Other articles of this Issue 3/2014

International Journal of Hematology 3/2014 Go to the issue

Original Article

Successful peripheral blood stem cell mobilization using pegfilgrastim in allogeneic stem cell transplantation

Progress in Hematology

From empiric to mechanism-based therapy for peripheral T cell lymphoma

Original Article

Phase I study of cladribine, cytarabine, granulocyte colony stimulating factor (CLAG regimen) and midostaurin and all-trans retinoic acid in relapsed/refractory AML

Original Article

The impact of C-Myc gene-related aberrations in newly diagnosed myeloma with bortezomib/dexamethasone therapy

Original Article

Effect of Swiss-type heterocellular HPFH from XmnI-Gγ and HBBP1 polymorphisms on HbF, HbE, MCV and MCH levels in Thai HbE carriers

Progress in Hematology

Microenvironment of adult T-cell leukemia/lymphoma-associated nodal lesions
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits